Celltrion announced on the 8th that Chairman Seo Jeong-jin and President Seo Jin-seok will participate in the '2025 JP Morgan Healthcare Conference (JPM),' the world's largest pharmaceutical and biopharmaceutical investment event.
Chairman Seo and President Seo will unveil the specific development timeline of the new drug pipeline (a group of candidate substances) for the first time on the 14th at 5:15 p.m. (local time) at the Grand Ballroom of the Westin St. Francis Hotel in San Francisco, followed by a Q&A session with investors.
This year’s presentation is set in the main track, the core stage of the event, continuing from last year. The main track presentations are conducted exclusively for a select few invited corporations that have a high status and growth potential in the global biotechnology industry, drawing the attention of global investors and industry stakeholders.
Celltrion is developing new drugs in advanced modalities, such as antibody-drug conjugates (ADCs) and multi-antibodies, leveraging its position and expertise as the 'home of antibodies,' having developed the world’s first antibody biosimilar and expanded a range of biosimilar products. The company plans to reveal the development achievements of its new drug pipeline thus far during this presentation. The new drug pipeline will include the ADC anticancer drugs CT-P70 and CT-P71, which were announced last year at World ADC.
Further, specific development plans for clinical entry per pipeline will also be disclosed. The schedule for developing a total of 13 new drug pipelines, including 9 ADCs and 4 multi-antibody new drugs, will be announced by 2028.
Recently, Celltrion has been solidifying a two-track strategy that encompasses both biosimilars and new drug development. The company is accelerating new drug development utilizing new modalities based on its autoimmune disease treatment drug, Jimpentra, which has settled in the U.S. market. It aims for the commercialization of the first product by 2029. Chairman Seo emphasized during a corporate briefing in Hong Kong at the end of last year that the goal is to generate 40% of sales from new drugs by 2030, adding that bold investments will continue to achieve this.
A representative of Celltrion said, 'Celltrion plans to substantially unveil the blueprint prepared for its leap to becoming a global new drug company through this JPM presentation,' adding that 'based on the capabilities and know-how established as the home of antibodies, it will carry out new drug development without a hitch to complete the blueprint and plans to emerge as a truly global big pharma.'